Prostate Cancer Predisposition

Yasin Bhanji; William B Isaacs; Jianfeng Xu; Kathleen A Cooney

doi:10.1016/j.ucl.2021.03.001

Prostate Cancer Predisposition

Urol Clin North Am. 2021 Aug;48(3):283-296. doi: 10.1016/j.ucl.2021.03.001. Epub 2021 Jun 12.

Authors

Yasin Bhanji¹, William B Isaacs², Jianfeng Xu³, Kathleen A Cooney⁴

Affiliations

¹ Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Marburg 134, 600 North Wolfe Street, Baltimore, MD 21287, USA.
² Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Marburg 115, 600 North Wolfe Street, Baltimore, MD 21287, USA. Electronic address: wisaacs1@jh.edu.
³ Program for Personalized Cancer Care, NorthShore University HealthSystem, 1001 University Place, Evanston, IL 60201, USA.
⁴ Department of Medicine, Duke University School of Medicine and the Duke Cancer Institute, 2301 Erwin Road, DUH 1102, Durham, NC 27710-3703, USA.

PMID: 34210485
DOI: 10.1016/j.ucl.2021.03.001

Abstract

The identification and characterization of alterations in prostate cancer (PCa)-predisposing genes can help to inform screening strategies in undiagnosed men and treatment options in men in both the clinically localized and in the metastatic setting. This review provides an overview of the genetic basis underlying hereditary predisposition to PCa, the current role of genetics and PCa risk assessment, and how genetic risk factors affect aggressiveness and lethality of PCa.

Keywords: Cancer susceptibility gene; Hereditary cancer syndrome; Polygenic risk score; Prostate cancer.

Publication types

Review

MeSH terms

Age Factors
Biomarkers, Tumor / genetics
Disease Progression
Genetic Predisposition to Disease*
Genetic Testing
Germ-Line Mutation
Humans
Male
Polymorphism, Single Nucleotide
Prostatic Neoplasms / epidemiology
Prostatic Neoplasms / ethnology
Prostatic Neoplasms / genetics*
Risk Factors

Substances

Biomarkers, Tumor